Study of miR-342-5pAnkG Pathway in Early Alzheimers Disease Synaptic Changes and Its Use in Diagnosis

What this Trial Is About

Alzheimers disease is the most common cause of memory loss in older adults, affecting memory, language, attention, and behavior. Researchers are investigating early changes in brain nerve cell connections that may lead to these symptoms. This study focuses on a specific pathway called miR-342-5pAnkG, which previous research suggests may be involved in these early brain changes and can be detected in blood and cerebrospinal fluid. The goal is to better understand these mechanisms and find biomarkers for early disease detection. Participants include people diagnosed with probable Alzheimers disease and healthy individuals of similar age. The study involves collecting peripheral blood samples and, if participants agree, cerebrospinal fluid samples as well. Two groups are studied one with Alzheimers disease and one healthy control group. The research team will analyze these samples to explore the relationship between the miR-342-5pAnkG pathway and synaptic proteins. During the 12 weeks after enrollment, participants will undergo assessments to measure the correlation between the pathway and synaptic proteins, cognitive function, and brain changes such as atrophy. Brain MRI scans and neurological exams are also part of the evaluation. This study aims to provide new insights for early diagnosis and better understanding of Alzheimers disease progression.

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction